Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion HealthCare Co Ltd    A091990   KR7091990002

CELLTRION HEALTHCARE CO LTD

(A091990)
  Report
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials
Sales 2020 1 757 B 1,59 B 1,59 B
Net income 2020 301 B 0,27 B 0,27 B
Net cash position 2020 436 B 0,39 B 0,39 B
P/E ratio 2020 61,9x
Yield 2020 -
Sales 2021 2 206 B 1,99 B 1,99 B
Net income 2021 348 B 0,31 B 0,31 B
Net cash position 2021 683 B 0,62 B 0,62 B
P/E ratio 2021 53,9x
Yield 2021 0,02%
Capitalization 18 285 B 16 504 M 16 512 M
EV / Sales 2020 10 405x
EV / Sales 2021 8 287x
Nbr of Employees -
Free-Float 60,8%
More Financials
Company
Celltrion Healthcare Co., Ltd. is a Korea-based company principally engaged in the marketing and distribution of biosimilar and biopharmaceutical medications developed and manufactured by Celltrion, Inc. The company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn’s disease, psoriasis, psoriatic arthritis and ulcerative colitis. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Notations Surperformance© of Celltrion HealthCare Co Ltd
Trading Rating : Investor Rating :
More Ratings
All news about CELLTRION HEALTHCARE CO LTD
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
RE
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
RE
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
RE
09/28S.Korea shares jump most in two weeks on falling virus cases, upbeat China da..
RE
09/27Investors swamp IPO for K-Pop band BTS management label, prices at top of ran..
RE
09/25South Korea's Celltrion to merge with affiliates to set up holding company st..
RE
06/19SK Biopharmaceuticals prices at top of range for South Korea's biggest IPO in..
RE
More news
News in other languages on CELLTRION HEALTHCARE CO LTD

- No features available -

More news
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 123 494,12 KRW
Last Close Price 122 100,00 KRW
Spread / Highest target 37,6%
Spread / Average Target 1,14%
Spread / Lowest Target -59,0%
EPS Revisions
Managers
NameTitle
Hyung-Ki Kim Chief Executive Officer & Director
Jung-Jin Seo Chairman
David Han Independent Director
Greg A. Belinfanti Independent Director
Eung-Yeol Choe Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION HEALTHCARE CO LTD16 504
CSL LIMITED11.34%99 427
SAMSUNG BIOLOGICS CO.,LTD.84.53%46 940
BIOGEN INC.-19.06%36 958
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.138.48%30 386
ALEXION PHARMACEUTICALS, INC.12.91%26 723